These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 18653594

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Méndez-Fernández R, López-Abad C, Matilla M, Garcia-Sanchez J.
    Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
    Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, Tanaka Y.
    Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
    [No Abstract] [Full Text] [Related]

  • 9. Anti-TNF-alpha therapy for uveitis: Behçet and beyond.
    Murray PI, Sivaraj RR.
    Eye (Lond); 2005 Aug; 19(8):831-3. PubMed ID: 16086039
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
    Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M.
    Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
    Bawazeer A, Raffa LH, Nizamuddin SH.
    Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
    [Abstract] [Full Text] [Related]

  • 12. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
    Kotter I, Deuter C, Stubiger N, Zierhut M.
    J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
    Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A.
    Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
    [Abstract] [Full Text] [Related]

  • 15. Adalimumab for sight-threatening uveitis in Behçet's disease.
    Mushtaq B, Saeed T, Situnayake RD, Murray PI.
    Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of infliximab on the acute attack of uveitis.
    Alokaily F, Alsaleh S, Al-Balawi M, Al-Rashidi S.
    Saudi Med J; 2010 Jan; 31(1):82-5. PubMed ID: 20062906
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
    Morris DS, Gavin MP, Sturrock RD.
    Adv Exp Med Biol; 2003 Jan; 528():557-9. PubMed ID: 12918763
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.